BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsEarnings

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690

Related news

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-05-06 11:00 EST

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

RAREUltragenyx Pharmaceutical2026-08-04 20:05 EST

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

AGIOAgios Pharmaceuticals, Inc.2026-07-30 10:30 EST

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Stock data

Close
9.30 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States